Biogen Inc BIIB:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
297.19 1.41   0.48%1,429,3601.8M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 12/2/2016

Latest News Headlines for Biogen Inc

Data Reinforcing the Long-Term Safety and -2-

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at

Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE(R) and ALPROLIX(R) Highlighted at 58th ASH Meeting

New Longitudinal Data Show Long-Term Prophylactic Use of ELOCTATE Resulted in Effective Target Joint Resolution and Improved Quality of Life Measures SAN DIEGO--(BUSINESS WIRE)--December 03, 2016--

BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016

NEW YORK, Nov. 30, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc. (NASDAQ: BIIB) securities between July 23, 2014 and July 23, 2015.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Allergan plc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Biogen Inc
Allergan plc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Biogen Inc
Allergan plc
Shire PLC (ADR)
Novo Nordisk A/S (ADR)
Abbott Laboratories
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open296.53
Previous Close295.78
Day High299.95
Day Low293.04
52 Week High8/2/2016 | 333.65
52 Week Low6/27/2016 | 223.0211
% Off 52 Week High(10.93)%
% Off 52 Week Low33.26%
Beta (5 Yr)0.74
Volatility Avg12/2/2016 | 35.42
10-Day Avg. Volume1,786,129
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2016 | 17.69
P/E Ratio9/30/2016 | 16.8
Market CapLarge Cap | 64.7B
Shares Outstanding217.57M

expand, down-facing arrow indicating expanded view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.63M
Short Ratio1.4
Short % of Float1.21%
As of 11/15/2016
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.